Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05876923 · ClinicalTrials.gov registry record · NA
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
A NA study of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT05876923: Recruiting NA study of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Mayo Clinic.
NCT05876923 is a NA study of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 70 participants, above the 44-participant average among 8 other Indolent Non-Hodgkin Lymphoma trials with a reported enrollment target (59% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05876923, a NA study of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.
Primary Outcome
A standardized questionnaire will be administered to assess levels of past and current physical activity. Baseline measurement of pulmonary function (PFT) will be collected and possibly a body composition scan via dual x-ray absorptiometry (DEXA). While subjects perform cardiopulmonary exercise testing (CPET), cardiopulmonary vitals will be assessed and monitored throughout exercise and in recovery. A 40 mL venous blood sample will be drawn at baseline and post exercise (80 mL total), along with
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Exercise Intervention
- OTHER Electronic Health Record Review
- OTHER Cardiopulmonary Exercise Testing
- PROCEDURE Dual X-ray Absorptiometry
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT05876923 shows while recruiting
NCT05876923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 44-participant average among 8 other Indolent Non-Hodgkin Lymphoma trials with a reported enrollment target (59% higher).
The record links to 2 conditions, with Indolent Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05876923 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05876923 about?
NCT05876923 is a clinical study titled "The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients". This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at ...
What is the current status of trial NCT05876923?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2023-06-12. Estimated completion is 2028-04.
What conditions does trial NCT05876923 study?
This clinical trial studies the following conditions: Indolent Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05876923?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Exercise Intervention (OTHER), Electronic Health Record Review (OTHER), Cardiopulmonary Exercise Testing (OTHER), Dual X-ray Absorptiometry (PROCEDURE).
Who is sponsoring clinical trial NCT05876923?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05876923 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Indolent Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05876923's enrollment target sits among peer trials
70 3rd of 8 higher than 6 of 8 other Indolent Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Indolent Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
RECRUITING · Phase 1
-
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI